In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eric Van Cutsem argues that EGFR antibodies are mandatory targeted therapy for RAS/BRAF wild-type left sided colon cancers.
Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER
© 2017 Imedex, LLC.
Advertisement